Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug	Cisplatin
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	nasopharyngeal cancer
ICD-0-3	C11
Methods	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP
Sample	nasopharyngeal cancer tissues, cell lines (FaDu, SCC25, HN30, HN4, SCC4, Cal27, HN13 and HN1)
Expression Pattern	up-regulated
Function Description	Quantitative real-time PCR (qRT-PCR) was performed to detect the lncRNA THOR expression in NPC and normal adjacent tissues, adherent NPC cells and non-adherent NPC spheres, and we found that THOR was significantly increased in NPC tissues and non-adherent NPC spheres. A greater expression of THORsignificantly correlated with both a larger tumor size (P?0.021),and a higher rate of lymph node metastasis. Further in vitro and in vivo experiments were carried out and identified that knockdown of THOR attenuated NPC cells stemness, characterized as the decrease of spheres formation ability, cell proliferation, migration, invasion, stemness markers expression and tumor initiation, and enhanced cisplatin sensitivity of NPC cells. Mechanistically, RNA immunoprecipitation (RIP), immunofluorescence and luciferase reporter analysis indicated that THOR could enhance YAP transcriptional activity via directly binding to YAP and suppressing its translocation from nuclear to cytoplasm. Notably, overexpression of YAP rescued the inhibition of THOR knockdown on NPC cells and spheres stemness and promotion on cisplatin sensitivity.
Pubmed ID	29959065
Year	2018
Title	LncRNA THOR Attenuates Cisplatin Sensitivity of Nasopharyngeal Carcinoma Cells via Enhancing Cells Stemness

External Links